Sammenligning av standardbehandling med en triplettkombinasjon av målrettede immunterapeutiske midler
En randomisert fase II-studie av triplettterapi (en PD-L1-hemmer Durvalumab (MEDI4736) i kombinasjon med Olaparib og Cediranib) sammenlignet med Olaparib og Cediranib eller Durvalumab (MEDI4736) og Cediranib eller Standard of Care-rekurrent Platinum-Resurrent med epitheli-kjemoterapi hos kvinner Ovariekreft, primær buk- eller egglederkreft som har mottatt tidligere bevacizumab
This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type of treatment most patients with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of durvalumab, olaparib and cediranib may work better in increasing the duration of time that the cancer does not progress compared to the usual treatment.
Studieoversikt
Status
Status
Forhold
Forhold
- Ovarialt seromucinøst karsinom
- Tilbakevendende ovarie høygradig serøst adenokarsinom
- Tilbakevendende platina-resistent ovariekarsinom
- Mucinøst adenokarsinom i egglederen
- Tilbakevendende adenokarsinom i egglederen
- Tilbakevendende endometrioid adenokarsinom i egglederen
- Tilbakevendende udifferensiert egglederkarsinom
- Tilbakevendende klarcellet adenokarsinom i eggstokkene
- Tilbakevendende ovarieendometrioid adenokarsinom
- Tilbakevendende ovarie-udifferensiert karsinom
- Tilbakevendende platina-resistent egglederkarsinom
- Tilbakevendende platinaresistent primært peritonealt karsinom
- Tilbakevendende primært peritonealt klarcellet adenokarsinom
- Tilbakevendende primært peritonealt endometrioid adenokarsinom
- Tilbakevendende primært peritonealt udifferensiert karsinom
- Platina-ildfast egglederkarsinom
- Platina-ildfast ovariekarsinom
- Platina-ildfast primært peritonealt karsinom
- Tilbakevendende eggleder av høy grad serøst adenokarsinom
- Tilbakevendende mucinøst adenokarsinom i egglederen
- Tilbakevendende fallopian Tube Transitional Cell Carcinoma
- Tilbakevendende lavgradig serøst adenokarsinom i egglederen
- Tilbakevendende ovarie lavgradig serøst adenokarsinom
- Tilbakevendende mucinøst adenokarsinom i eggstokkene
- Tilbakevendende seromucinøs ovariekarsinom
- Tilbakevendende overgangscellekarsinom i eggstokkene
- Tilbakevendende primært peritonealt høygradig serøst adenokarsinom
- Tilbakevendende primært peritonealt lavgradig serøst adenokarsinom
- Tilbakevendende primært peritonealt overgangscellekarsinom
- Ildfast eggleder klarcellet adenokarsinom
- Refraktært eggleder endometrioid adenokarsinom
- Ildfast eggleder av høy grad av serøst adenokarsinom
- Ildfast eggleder mucinøst adenokarsinom
- Ildfast fallopian Tube Transitional Cell Carcinoma
- Refraktært udifferensiert egglederkarsinom
- Ildfast lavgradig eggleder serøst adenokarsinom
- Refraktært klarcellet ovarieadenokarsinom
- Refraktært ovarieendometrioid adenokarsinom
- Refraktært ovarie høygradig serøst adenokarsinom
- Ildfast ovarie lavgradig serøst adenokarsinom
- Refraktært ovarie mucinøst adenokarsinom
- Refraktært seromucinøst ovariekarsinom
- Ildfast ovarieovergangscellekarsinom
- Refraktært udifferensiert ovariekarsinom
- Refraktært primært peritonealt klarcellet adenokarsinom
- Refraktært primært peritonealt endometrioid adenokarsinom
- Refraktært primært peritonealt høygradig serøst adenokarsinom
- Refraktært primært peritonealt lavgradig serøst adenokarsinom
- Refraktært primært peritonealt overgangscellekarsinom
- Refraktært primært peritonealt udifferensiert karsinom
Intervensjon / Behandling
Intervensjon / Behandling
- Legemiddel: Paclitaxel
- Fremgangsmåte: Computed Tomography
- Fremgangsmåte: Magnetic Resonance Imaging
- Fremgangsmåte: Echocardiography Test
- Fremgangsmåte: Multigated Acquisition Scan
- Fremgangsmåte: Biospecimen Collection
- Legemiddel: Cediranib Maleate
- Legemiddel: Olaparib
- Legemiddel: Pegylated Liposomal Doxorubicin Hydrochloride
- Legemiddel: Topotecan Hydrochloride
- Fremgangsmåte: Computed Tomography with Contrast
- Biologisk: Durvalumab
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by progression-free survival (PFS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.
SECONDARY OBJECTIVES:
I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.
II. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by overall survival (OS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.
OUTLINE: Patients are randomized to 1 of 4 arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on study. Patients also undergo collection of blood and computed tomography (CT) with contrast during screening, and CT or magnetic resonance imaging (MRI) scans throughout the trial.
ARM II: Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate orally (PO) once daily (QD) Monday through Friday, and olaparib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
ARM III: Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
ARM IV: Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
After completion of study treatment, patients are followed up periodically for up to 5 years.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Forente stater, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Forente stater, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Forente stater, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Forente stater, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Forente stater, 99504
- Anchorage Radiation Therapy Center
-
Fairbanks, Alaska, Forente stater, 99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Goodyear, Arizona, Forente stater, 85338
- CTCA at Western Regional Medical Center
-
Phoenix, Arizona, Forente stater, 85004
- Cancer Center at Saint Joseph's
-
-
Arkansas
-
Fort Smith, Arkansas, Forente stater, 72903
- Mercy Hospital Fort Smith
-
Hot Springs, Arkansas, Forente stater, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
Little Rock, Arkansas, Forente stater, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Arroyo Grande, California, Forente stater, 93420
- Mission Hope Medical Oncology - Arroyo Grande
-
Auburn, California, Forente stater, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Forente stater, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Berkeley, California, Forente stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Burbank, California, Forente stater, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Cameron Park, California, Forente stater, 95682
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Castro Valley, California, Forente stater, 94546
- Eden Hospital Medical Center
-
Concord, California, Forente stater, 94520
- John Muir Medical Center-Concord
-
Davis, California, Forente stater, 95616
- Sutter Davis Hospital
-
Duarte, California, Forente stater, 91010
- City of Hope Comprehensive Cancer Center
-
Fremont, California, Forente stater, 94538
- Palo Alto Medical Foundation-Fremont
-
Lancaster, California, Forente stater, 93534
- City of Hope Antelope Valley
-
Los Angeles, California, Forente stater, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Forente stater, 90033
- Los Angeles General Medical Center
-
Modesto, California, Forente stater, 95355
- Memorial Medical Center
-
Mountain View, California, Forente stater, 94040
- Palo Alto Medical Foundation-Camino Division
-
Mountain View, California, Forente stater, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Palo Alto, California, Forente stater, 94301
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Forente stater, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Forente stater, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Forente stater, 95816
- Sutter Medical Center Sacramento
-
San Francisco, California, Forente stater, 94115
- California Pacific Medical Center-Pacific Campus
-
San Luis Obispo, California, Forente stater, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Santa Cruz, California, Forente stater, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Maria, California, Forente stater, 93444
- Mission Hope Medical Oncology - Santa Maria
-
Santa Rosa, California, Forente stater, 95403
- Sutter Pacific Medical Foundation
-
South Pasadena, California, Forente stater, 91030
- City of Hope South Pasadena
-
Sunnyvale, California, Forente stater, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Upland, California, Forente stater, 91786
- City of Hope Upland
-
Vallejo, California, Forente stater, 94589
- Sutter Solano Medical Center/Cancer Center
-
Walnut Creek, California, Forente stater, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Boulder, Colorado, Forente stater, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Centennial, Colorado, Forente stater, 80112
- Rocky Mountain Cancer Centers - Centennial
-
Colorado Springs, Colorado, Forente stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forente stater, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Denver, Colorado, Forente stater, 80210
- AdventHealth Porter
-
Durango, Colorado, Forente stater, 81301
- Mercy Medical Center
-
Durango, Colorado, Forente stater, 81301
- CommonSpirit Cancer Center Mercy
-
Lakewood, Colorado, Forente stater, 80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton, Colorado, Forente stater, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Littleton, Colorado, Forente stater, 80122
- AdventHealth Littleton
-
Lone Tree, Colorado, Forente stater, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Longmont, Colorado, Forente stater, 80501
- Longmont United Hospital
-
Longmont, Colorado, Forente stater, 80501
- Rocky Mountain Cancer Centers-Longmont
-
Loveland, Colorado, Forente stater, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker, Colorado, Forente stater, 80138
- AdventHealth Parker
-
Pueblo, Colorado, Forente stater, 81004
- Saint Mary Corwin Medical Center
-
-
Connecticut
-
Danbury, Connecticut, Forente stater, 06810
- Danbury Hospital
-
Norwalk, Connecticut, Forente stater, 06856
- Norwalk Hospital
-
-
Florida
-
Pensacola, Florida, Forente stater, 32504
- Sacred Heart Hospital
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30342
- Northside Hospital
-
Newnan, Georgia, Forente stater, 30265
- CTCA at Southeastern Regional Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Forente stater, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Forente stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forente stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Forente stater, 83814
- Kootenai Health - Coeur d'Alene
-
Emmett, Idaho, Forente stater, 83617
- Walter Knox Memorial Hospital
-
Fruitland, Idaho, Forente stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forente stater, 83642
- Idaho Urologic Institute-Meridian
-
Meridian, Idaho, Forente stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forente stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forente stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Forente stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Forente stater, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Forente stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Alton, Illinois, Forente stater, 62002
- OSF Saint Anthony's Health Center
-
Aurora, Illinois, Forente stater, 60504
- Rush-Copley Medical Center
-
Bloomington, Illinois, Forente stater, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Forente stater, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Forente stater, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Forente stater, 62918
- SIH Cancer Institute
-
Carthage, Illinois, Forente stater, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forente stater, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Forente stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Forente stater, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Forente stater, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, Forente stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forente stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forente stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Forente stater, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forente stater, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Forente stater, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Forente stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Forente stater, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Forente stater, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Forente stater, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Forente stater, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Harvey, Illinois, Forente stater, 60426
- Ingalls Memorial Hospital
-
Highland Park, Illinois, Forente stater, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Hinsdale, Illinois, Forente stater, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Kewanee, Illinois, Forente stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Forente stater, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Forente stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, Forente stater, 62864
- SSM Health Good Samaritan
-
New Lenox, Illinois, Forente stater, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Forente stater, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Forente stater, 60462
- University of Chicago Medicine-Orland Park
-
Ottawa, Illinois, Forente stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Forente stater, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forente stater, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Forente stater, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Forente stater, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Forente stater, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Forente stater, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Forente stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forente stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forente stater, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
Urbana, Illinois, Forente stater, 61801
- The Carle Foundation Hospital
-
Warrenville, Illinois, Forente stater, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, Forente stater, 61571
- Illinois CancerCare - Washington
-
Yorkville, Illinois, Forente stater, 60560
- Rush-Copley Healthcare Center
-
Zion, Illinois, Forente stater, 60099
- Midwestern Regional Medical Center
-
-
Indiana
-
South Bend, Indiana, Forente stater, 46601
- Memorial Hospital of South Bend
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic - Ames
-
Boone, Iowa, Forente stater, 50036
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, Forente stater, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, Forente stater, 52403
- Oncology Associates at Mercy Medical Center
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Forente stater, 51503
- Alegent Health Mercy Hospital
-
Creston, Iowa, Forente stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Forente stater, 50501
- McFarland Clinic - Trinity Cancer Center
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson, Iowa, Forente stater, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Forente stater, 50158
- McFarland Clinic - Marshalltown
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Garden City, Kansas, Forente stater, 67846
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Forente stater, 67530
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Bardstown, Kentucky, Forente stater, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin, Kentucky, Forente stater, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Forente stater, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Forente stater, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
London, Kentucky, Forente stater, 40741
- CommonSpirit Saint Joseph Hospital London
-
Louisville, Kentucky, Forente stater, 40202
- Jewish Hospital
-
Louisville, Kentucky, Forente stater, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Forente stater, 40215
- Saints Mary and Elizabeth Hospital
-
Shepherdsville, Kentucky, Forente stater, 40165
- Jewish Hospital Medical Center South
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70817
- Our Lady of the Lake Medical Oncology
-
-
Maine
-
Augusta, Maine, Forente stater, 04330
- Harold Alfond Center for Cancer Care
-
Brewer, Maine, Forente stater, 04412
- Lafayette Family Cancer Center-EMMC
-
Scarborough, Maine, Forente stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21204
- Greater Baltimore Medical Center
-
Bethesda, Maryland, Forente stater, 20892
- National Institutes of Health Clinical Center
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- University of Michigan Rogel Cancer Center
-
Dearborn, Michigan, Forente stater, 48124
- Corewell Health Dearborn Hospital
-
Royal Oak, Michigan, Forente stater, 48073
- Corewell Health William Beaumont University Hospital
-
Troy, Michigan, Forente stater, 48085
- Corewell Health Beaumont Troy Hospital
-
-
Minnesota
-
Burnsville, Minnesota, Forente stater, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Forente stater, 55337
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Forente stater, 55008
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Forente stater, 55433
- Mercy Hospital
-
Edina, Minnesota, Forente stater, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Forente stater, 55432
- Unity Hospital
-
Maple Grove, Minnesota, Forente stater, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Forente stater, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Forente stater, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Forente stater, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Forente stater, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Forente stater, 55454
- Health Partners Inc
-
Minneapolis, Minnesota, Forente stater, 55455
- University of Minnesota/Masonic Cancer Center
-
Monticello, Minnesota, Forente stater, 55362
- Monticello Cancer Center
-
New Ulm, Minnesota, Forente stater, 56073
- New Ulm Medical Center
-
Princeton, Minnesota, Forente stater, 55371
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Forente stater, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Forente stater, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Forente stater, 55102
- United Hospital
-
Shakopee, Minnesota, Forente stater, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Forente stater, 55082
- Lakeview Hospital
-
Waconia, Minnesota, Forente stater, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Forente stater, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Forente stater, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Forente stater, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin, Missouri, Forente stater, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Forente stater, 65613
- Central Care Cancer Center - Bolivar
-
Cape Girardeau, Missouri, Forente stater, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Forente stater, 63703
- Mercy Cancer Center - Cape Girardeau
-
Farmington, Missouri, Forente stater, 63640
- Parkland Health Center - Farmington
-
Jefferson City, Missouri, Forente stater, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Forente stater, 64804
- Freeman Health System
-
Joplin, Missouri, Forente stater, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Forente stater, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Forente stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Forente stater, 64506
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Forente stater, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Forente stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forente stater, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Forente stater, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forente stater, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Forente stater, 63080
- Missouri Baptist Sullivan Hospital
-
Washington, Missouri, Forente stater, 63090
- Mercy Hospital Washington
-
-
Montana
-
Anaconda, Montana, Forente stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forente stater, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Forente stater, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Forente stater, 59405
- Great Falls Clinic
-
Great Falls, Montana, Forente stater, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Forente stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forente stater, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Forente stater, 59804
- Community Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Forente stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Forente stater, 68847
- CHI Health Good Samaritan
-
Lincoln, Nebraska, Forente stater, 68510
- Saint Elizabeth Regional Medical Center
-
Lincoln, Nebraska, Forente stater, 68516
- Cancer Partners of Nebraska
-
Omaha, Nebraska, Forente stater, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Forente stater, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Forente stater, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Forente stater, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Forente stater, 68130
- Alegent Health Lakeside Hospital
-
Papillion, Nebraska, Forente stater, 68046
- Midlands Community Hospital
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89106
- Women's Cancer Center of Nevada
-
-
New Jersey
-
Neptune City, New Jersey, Forente stater, 07753
- Jersey Shore Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- University of New Mexico Cancer Center
-
Las Cruces, New Mexico, Forente stater, 88011
- Memorial Medical Center-Las Cruces
-
Rio Rancho, New Mexico, Forente stater, 87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Bay Shore, New York, Forente stater, 11706
- Northwell Health Imbert Cancer Center
-
Brightwaters, New York, Forente stater, 11718
- Island Gynecologic Oncology
-
Buffalo, New York, Forente stater, 14263
- Roswell Park Cancer Institute
-
Lake Success, New York, Forente stater, 11042
- Northwell Health/Center for Advanced Medicine
-
Syracuse, New York, Forente stater, 13210
- State University of New York Upstate Medical University
-
White Plains, New York, Forente stater, 10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Clinton, North Carolina, Forente stater, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Forente stater, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville, North Carolina, Forente stater, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
-
Ohio
-
Akron, Ohio, Forente stater, 44304
- Summa Health System - Akron Campus
-
Alliance, Ohio, Forente stater, 44601
- Aultman Alliance Community Hospital
-
Beachwood, Ohio, Forente stater, 44122
- UHHS-Chagrin Highlands Medical Center
-
Belpre, Ohio, Forente stater, 45714
- Strecker Cancer Center-Belpre
-
Canton, Ohio, Forente stater, 44710
- Aultman Health Foundation
-
Centerville, Ohio, Forente stater, 45459
- Miami Valley Hospital South
-
Chardon, Ohio, Forente stater, 44024
- Geauga Hospital
-
Chillicothe, Ohio, Forente stater, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Forente stater, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Forente stater, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Forente stater, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Forente stater, 45255
- TriHealth Cancer Institute-Anderson
-
Cleveland, Ohio, Forente stater, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Forente stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Forente stater, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Forente stater, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Forente stater, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Forente stater, 43228
- Doctors Hospital
-
Columbus, Ohio, Forente stater, 43213
- Mount Carmel East Hospital
-
Columbus, Ohio, Forente stater, 43215
- Grant Medical Center
-
Columbus, Ohio, Forente stater, 43222
- Mount Carmel Health Center West
-
Dayton, Ohio, Forente stater, 45409
- Miami Valley Hospital
-
Delaware, Ohio, Forente stater, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Forente stater, 43015
- Grady Memorial Hospital
-
Dublin, Ohio, Forente stater, 43016
- Dublin Methodist Hospital
-
Gahanna, Ohio, Forente stater, 43230
- Central Ohio Breast and Endocrine Surgery
-
Grove City, Ohio, Forente stater, 43123
- Mount Carmel Grove City Hospital
-
Lancaster, Ohio, Forente stater, 43130
- Fairfield Medical Center
-
Lima, Ohio, Forente stater, 45801
- Saint Rita's Medical Center
-
Mansfield, Ohio, Forente stater, 44903
- OhioHealth Mansfield Hospital
-
Marietta, Ohio, Forente stater, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Forente stater, 43302
- OhioHealth Marion General Hospital
-
Mayfield Heights, Ohio, Forente stater, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, Forente stater, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Mount Vernon, Ohio, Forente stater, 43050
- Knox Community Hospital
-
Newark, Ohio, Forente stater, 43055
- Licking Memorial Hospital
-
Newark, Ohio, Forente stater, 43055
- Newark Radiation Oncology
-
Perrysburg, Ohio, Forente stater, 43551
- Mercy Health - Perrysburg Hospital
-
Portsmouth, Ohio, Forente stater, 45662
- Southern Ohio Medical Center
-
Toledo, Ohio, Forente stater, 43623
- Mercy Health - Saint Anne Hospital
-
Toledo, Ohio, Forente stater, 43608
- Mercy Health - Saint Vincent Hospital
-
Wadsworth, Ohio, Forente stater, 44281
- University Hospitals Sharon Health Center
-
Westerville, Ohio, Forente stater, 43081
- Saint Ann's Hospital
-
Westlake, Ohio, Forente stater, 44145
- UH Seidman Cancer Center at Saint John Medical Center
-
Zanesville, Ohio, Forente stater, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Lawton, Oklahoma, Forente stater, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Forente stater, 73120
- Mercy Hospital Oklahoma City
-
Tulsa, Oklahoma, Forente stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Baker City, Oregon, Forente stater, 97814
- Saint Alphonsus Cancer Care Center-Baker City
-
Bend, Oregon, Forente stater, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Forente stater, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Forente stater, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Forente stater, 97420
- Bay Area Hospital
-
Newberg, Oregon, Forente stater, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Forente stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Forente stater, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Forente stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forente stater, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Forente stater, 97756
- Saint Charles Health System-Redmond
-
Tualatin, Oregon, Forente stater, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Butler, Pennsylvania, Forente stater, 16001
- UPMC Hillman Cancer Center at Butler Health System
-
Erie, Pennsylvania, Forente stater, 16505
- UPMC Hillman Cancer Center Erie
-
Paoli, Pennsylvania, Forente stater, 19301
- Paoli Memorial Hospital
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Forente stater, 19114
- Jefferson Torresdale Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- UPMC-Magee Womens Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15237
- UPMC-Passavant Hospital
-
Willow Grove, Pennsylvania, Forente stater, 19090
- Asplundh Cancer Pavilion
-
Wynnewood, Pennsylvania, Forente stater, 19096
- Lankenau Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Forente stater, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of South Carolina
-
Greenville, South Carolina, Forente stater, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Forente stater, 29601
- Saint Francis Hospital
-
-
South Dakota
-
Rapid City, South Dakota, Forente stater, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Bristol, Tennessee, Forente stater, 37620
- Bristol Regional Medical Center
-
Kingsport, Tennessee, Forente stater, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Forente stater, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Knoxville, Tennessee, Forente stater, 37916
- Covenant Health Cancer Centers
-
Knoxville, Tennessee, Forente stater, 37932
- Covenant Health Cancer Centers - West
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Forente stater, 37204
- Vanderbilt Breast Center at One Hundred Oaks
-
-
Texas
-
Bryan, Texas, Forente stater, 77802
- Saint Joseph Regional Cancer Center
-
Dallas, Texas, Forente stater, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Forente stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, Forente stater, 77030
- Houston Methodist Hospital
-
Houston, Texas, Forente stater, 77070
- Methodist Willowbrook Hospital
-
Houston, Texas, Forente stater, 77094
- Houston Methodist West Hospital
-
Sugar Land, Texas, Forente stater, 77479
- Houston Methodist Sugar Land Hospital
-
The Woodlands, Texas, Forente stater, 77385
- Houston Methodist The Woodlands Hospital
-
-
Virginia
-
Bristol, Virginia, Forente stater, 24201
- Ballad Health Cancer Care - Bristol
-
Norton, Virginia, Forente stater, 24273
- Ballad Health Cancer Care - Norton
-
-
Washington
-
Aberdeen, Washington, Forente stater, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Forente stater, 98225
- PeaceHealth Saint Joseph Medical Center
-
Burien, Washington, Forente stater, 98166
- Saint Anne Hospital
-
Centralia, Washington, Forente stater, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Forente stater, 98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw, Washington, Forente stater, 98022
- Saint Elizabeth Hospital
-
Everett, Washington, Forente stater, 98201
- Providence Regional Cancer Partnership
-
Federal Way, Washington, Forente stater, 98003
- Saint Francis Hospital
-
Issaquah, Washington, Forente stater, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Forente stater, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Forente stater, 98503
- Providence Regional Cancer System-Lacey
-
Lakewood, Washington, Forente stater, 98499
- Saint Clare Hospital
-
Longview, Washington, Forente stater, 98632
- PeaceHealth Saint John Medical Center
-
Port Townsend, Washington, Forente stater, 98368
- Jefferson Healthcare
-
Seattle, Washington, Forente stater, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Forente stater, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Forente stater, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Forente stater, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Forente stater, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Forente stater, 98584
- Providence Regional Cancer System-Shelton
-
Silverdale, Washington, Forente stater, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Tacoma, Washington, Forente stater, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver, Washington, Forente stater, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Forente stater, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Forente stater, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Forente stater, 98597
- Providence Regional Cancer System-Yelm
-
-
West Virginia
-
Charleston, West Virginia, Forente stater, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Green Bay, Wisconsin, Forente stater, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Forente stater, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
La Crosse, Wisconsin, Forente stater, 54601
- Gundersen Lutheran Medical Center
-
Milwaukee, Wisconsin, Forente stater, 53226
- Medical College of Wisconsin
-
Mukwonago, Wisconsin, Forente stater, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Forente stater, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Forente stater, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oconto Falls, Wisconsin, Forente stater, 54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Sturgeon Bay, Wisconsin, Forente stater, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Waukesha, Wisconsin, Forente stater, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Forente stater, 53188
- ProHealth Waukesha Memorial Hospital
-
-
Wyoming
-
Cody, Wyoming, Forente stater, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Forente stater, 82801
- Welch Cancer Center
-
-
-
-
-
Bayamón, Puerto Rico, 00959-5060
- Cancer Center-Metro Medical Center Bayamon
-
Caguas, Puerto Rico, 00726
- HIMA San Pablo Oncologic Hospital
-
Manati, Puerto Rico, 00674
- Doctors Cancer Center
-
Ponce, Puerto Rico, 00716
- Instituto Oncologia Moderna Ponce
-
San Juan, Puerto Rico, 00917
- San Juan Community Oncology Group
-
San Juan, Puerto Rico, 00927
- Centro Comprensivo de Cancer de UPR
-
San Juan, Puerto Rico, 00936
- San Juan City Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Women with recurrent/persistent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers; platinum-resistant disease is defined as progression within < 6 months from completion of platinum based therapy. The date should be calculated from the last administered dose of platinum therapy
-
Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of high grade serous, grade 3 endometrioid or clear cell carcinoma based on local histopathological findings. Patients with low grade serous, grade 1 or 2 endometrioid, mixed epithelial, undifferentiated carcinoma, or mucinous carcinoma histologies are also eligible, provided that the patient has a known deleterious BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory. Histologic confirmation of the original primary tumor is required via the pathology report (upload of report required). Confirmation of BRCA1 and BRCA2 germline and/or somatic mutation status and hormone receptor (HR) status is required for all entered patients (if available) via testing report (upload of report[s] required)
-
Evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a CA125 >= 2 x upper limit of normal [ULN])
-
Prior therapy:
- At least two prior treatment regimens (including primary therapy) but up to 5 lines of systemic anticancer therapy. Hormonal therapy (such as tamoxifen, aromatase inhibitors) will not count as a previous treatment regimen.
- Prior use of bevacizumab in the upfront or recurrent setting is required.
- Prior use of PARP inhibitor is allowed.
- Prior use of immune checkpoint blockade (e.g., a PD-L1/PD-1inhibitor or a CTLA-4 inhibitor) is allowed
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
-
Absolute neutrophil count (ANC) >= 1,500/mcL
-
Hemoglobin >= 10 g/dL
-
Platelets >= 100,000/mcL
-
Creatinine clearance (CrCL) or estimated glomerular filtration rate (eGFR) of > 50 mL/min estimated using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR)
-
Urine protein: creatinine ratio (UPC) of =< 1
-
Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
-
Age >= 18 years
-
Body weight > 30 kg
-
Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on a maximum of three antihypertensive medications. Patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to study registration. It is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on protocol. Patients must be willing and able to check and record daily blood pressure readings. BP cuffs will be provided to patients randomized to the cediranib-containing arms
-
Adequately controlled thyroid dysfunction with no symptoms of thyroid dysfunction and normal thyroid stimulating hormone (TSH). If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal free T4 level is required
-
Able to swallow and retain oral medications and no gastrointestinal (GI) illnesses that would preclude absorption of olaparib and cediranib as judged by treating physician
-
Toxicities of prior therapy (excepting alopecia and vitiligo), should be resolved to less than or equal to grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0
-
Women of childbearing potential (WOCBP) must agree to use two forms of birth control (hormonal or barrier method of birth control; abstinence). Note: Definition of women of no longer having childbearing potential: Postmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within 7 days prior to start of study treatment. Postmenopausal is defined as: Age >= 60 years, or age < 60 with any one or more of the conditions below:
- Amenorrhoeic for >= 1 year in the absence of chemotherapy and/or hormonal treatments,
- Luteinizing hormone and/or follicle stimulating hormone and/or estradiol levels in the post-menopausal range,
- Radiation-induced oophorectomy with last menses > 1 year ago,
- Chemotherapy-induced menopause with > 1 year interval since last menses,
- Surgical sterilization (bilateral oophorectomy or hysterectomy)
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and authorization permitting release of personal health information
Exclusion Criteria:
-
Primary platinum-refractory disease defined as progression during first-line platinum-based chemotherapy
-
Rising CA-125 only without RECIST 1.1 evaluable disease
-
Prior therapy:
-
Patients who have had chemotherapy, investigational drugs or radiotherapy within 3 weeks prior to study registration or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.
-
Patients may not have had hormonal therapy within 2 weeks of study registration. Patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions.
-
Prior use of concurrent olaparib and cediranib combination.
-
Patients who have experienced immune-mediated adverse events requiring dose modification or discontinuation.
-
For patients who have received prior PARP inhibitor:
- Patients who have required dose modification or dose reduction of olaparib will not be eligible, as they will not be able to start this study at full dose.
- Patients who have required dose reduction of non-olaparib PARP inhibitors for hematologic adverse events will not be eligible (Note: niraparib that is initiated at 200mg daily per weight and platelet guidelines is not considered a dose reduction).
- Patients who required dose-reduction of non-olaparib PARP inhibitors for non-hematologic adverse events may be eligible after discussion with the Study Chair if the treating investigator feels that they could appropriately receive olaparib at full dose.
-
-
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 3 months prior to study registration
-
Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months of study registration except temporary (< 24 hr) improved with medical management, within last 3 months
-
Any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1
-
Dependency on IV hydration or total parenteral nutrition (TPN)
-
Pregnant women. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with these drugs, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events. Patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study registration
-
Patients who have the following clinical conditions are considered to be at increased risk for cardiac toxicities. Patients with any cardiac history of the following conditions:
- History of myocardial infarction or myocarditis within six months of study registration
- Unstable angina
- Resting electrocardiogram (ECG) with clinically significant abnormal findings.
- New York Heart Association functional classification of III or IV
-
If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines. Patients with the following risk factors should have a baseline cardiac function assessment:
- Prior treatment with anthracyclines
- Prior treatment with trastuzumab or T-DM1
- Prior central thoracic radiation therapy (RT), including RT to the heart
- History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)
- Prior history of impaired cardiac function
-
History of stroke or transient ischemic attack within six months of study registration
-
Clinically significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)
-
Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatment. Patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable
-
Evidence of coagulopathy or bleeding diathesis. Therapeutic anticoagulation for prior thromboembolic events, including warfarin, is permitted. Patients receiving warfarin are recommended to have careful monitoring of international normalized ratio (INR)
-
Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated. No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)
-
Human immunodeficiency virus (HIV) positive patients due to potential drug and drug interactions
-
Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments
-
Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment
-
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring adverse events or compromise the ability of the patient to given written informed consent
-
Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4. Dihydropyridine calcium-channel blockers are permitted for management of hypertension
-
Current or prior use of immunosuppressive medication within 14 days of study registration. The following are exceptions to this criterion:
- Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
- Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab, olaparib, or cediranib
-
Patients with active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
-
Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis [TB] testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen (HBsAg) result), or hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for hepatitis C virus (HCV) ribonucleic acid (RNA)
-
Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Aktiv komparator: Arm I (paclitaxel, doxorubicin, topotecan hydrochloride))
Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial. |
Given IV
Andre navn:
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo ECHO
Andre navn:
Undergo MUGA
Andre navn:
Undergo collection of blood
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Undergo CT with contrast
Andre navn:
|
|
Eksperimentell: Arm II (durvalumab, cediranib maleate, olaparib)
Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate PO QD Monday through Friday, and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial. |
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo ECHO
Andre navn:
Undergo MUGA
Andre navn:
Undergo collection of blood
Andre navn:
Given PO
Andre navn:
Given PO
Andre navn:
Undergo CT with contrast
Andre navn:
Given IV
Andre navn:
|
|
Eksperimentell: Arm III (durvalumab, cediranib maleate)
Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial. |
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo ECHO
Andre navn:
Undergo MUGA
Andre navn:
Undergo collection of blood
Andre navn:
Given PO
Andre navn:
Undergo CT with contrast
Andre navn:
Given IV
Andre navn:
|
|
Eksperimentell: Arm IV (cediranib maleate, olaparib)
Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial. |
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo ECHO
Andre navn:
Undergo collection of blood
Andre navn:
Given PO
Andre navn:
Given PO
Andre navn:
Undergo CT with contrast
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression Free Survival
Tidsramme: From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months).
|
The relationship of randomized treatment assignment to progression free survival. The RECIST 1.1 criteria are used for disease progression. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months).
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate
Tidsramme: From the start of the treatment until disease progression/recurrence, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
Determination of response should take into consideration all target and non-target lesions. Here are the definitions of CR, PR, PD and SD: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters (i.e. the nadir) while on study. The CI is the Jeffreys interval. |
From the start of the treatment until disease progression/recurrence, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
|
Duration of Response
Tidsramme: Throughout study treatment, up to 10.6 months.
|
Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. Duration of response was defined as the time from the first documentation of objective tumor response (complete response (CR) or partial response (PR)) to the first documented progressive disease (PD), or to death due to any cause, whichever occurs first. Per RECIST, Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as an >=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Reporting the number of months from complete or partial response until disease progression, death or censoring, whichever occurs first. In the absence of disease progression or death, censoring time is based on date of last CT scan. |
Throughout study treatment, up to 10.6 months.
|
|
Overall Survival
Tidsramme: Time from study entry to date of death from any cause, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
Overall survival will be presented by Kaplan Meier methods. Overall Survival (OS) is defined as the duration of time from study entry to date of death from any cause. A subject who has not died will be censored on the date that they were last known to be alive. |
Time from study entry to date of death from any cause, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
|
Count of Participants With a Grade 3 (or Higher) Adverse Event
Tidsramme: From the start of treatment until disease progression/recurrence or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
The number of patients (in each reporting group) who experienced a grade 3 (or higher) adverse event |
From the start of treatment until disease progression/recurrence or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Jung-min Lee, NRG Oncology
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser
- Undersøkelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Farmakologiske handlinger
- Kjemiske handlinger og bruk
- Hydrokarboner
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Terpener
- Karbohydrater
- Camptothecin
- Alkaloider
- Polysykliske aromatiske hydrokarboner
- Hydrokarboner, aromatisk
- Polysykliske forbindelser
- Glykosider
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Uorganiske kjemikalier
- Taxoider
- Cyclodecanes
- Diterpenes
- Helsevesenets økonomi og organisasjoner
- Spesialbruk av kjemikalier
- Kjemisteknikker, analytisk
- Spektrumanalyse
- Antracykliner
- Naphthacenes
- Aminoglykosider
- Immunoglobulinisotyper
- Sulfider
- Anioner
- Ioner
- Elektrolytter
- Hydrogensulfid
- Daunorubicin
- Diagnostisk bruk av kjemikalier
- Økonomi
- Doxorubicin
- Paclitaxel
- Immunoglobulin G
- Topotekan
- Prøvehåndtering
- Magnetisk resonansspektroskopi
- Durvalumab
- Disulfider
- Liposomal doxorubicin
- olaparib
- Cediranib
- Kontrastmedier
- Skatter
Andre studie-ID-numre
Andre studie-ID-numre
- NCI-2021-00615
- U10CA180868 (U.S. NIH-stipend/kontrakt)
- NCI-2021-00615 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- NRG-GY023 (Annen identifikator: CTEP)
- NRG-GY023 (Annen identifikator: NRG Oncology)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .